Brief: Health Canada Clears Appili Therapeutics' Phase 2 Clinical Trial Evaluating Favipiravir As A Prophylactic Agent Against Covid-19 Outbreaks
21/05/2020 12:28
May 21 (Reuters) - Appili Therapeutics Inc APLI.V :
* HEALTH CANADA CLEARS APPILI THERAPEUTICS’ PHASE 2 CLINICAL
TRIAL
EVALUATING FAVIPIRAVIR AS A PROPHYLACTIC AGENT AGAINST COVID-19
OUTBREAKS
* APPILI THERAPEUTICS - APPILI EXPECTS TRIAL RECRUITMENT TO
BEGIN
IMMINENTLY
* APPILI THERAPEUTICS - RESEARCHERS WILL ENROLL
APPROXIMATELY 760
SUBJECTS, BOTH RESIDENTS AND STAFF, AT 16 LONG-TERM CARE HOMES
(LTCHS) IN ONTARIO
Source text for Eikon: ID:nBwbDqSBxa
Further company coverage: APLI.V
(Reuters.Briefs@thomsonreuters.com)
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez